Thiolactomycin Analog Modifications at 3 and 4 Positions
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current efforts to develop thiolactomycin analogs with improved antibacterial activity have focused on the 5 position, but these efforts have not successfully enhanced the activity of the compound, despite understanding its mechanism as a selective inhibitor of KAS enzymes in the FAS-II pathway.
Innovation Solution
The development of thiolactomycin analogs with modifications at the 3 and 4 positions, utilizing NMR spectroscopy and fragment-based inhibitor assembly, to improve the interaction with KAS enzymes, specifically targeting KasA and KasB enzymes in bacteria like Mycobacterium tuberculosis and Escherichia coli.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If thiolactomycin analogs are modified at the 5 position to improve antibacterial activity, then synthesis ease is improved, but antibacterial activity is not enhanced
Solution Approach 1:
The patent applies local quality by modifying thiolactomycin analogs at specific positions (3 and/or 4 positions) rather than uniformly at the 5 position. This localized modification strategy allows optimization of binding affinity at the KAS enzyme active site while maintaining synthetic feasibility, thereby resolving the contradiction between ease of manufacture and antibacterial activity.
Solution Approach 2:
The patent employs parameter changes by systematically varying substituent groups at the 3 and/or 4 positions of the thiolactomycin core structure. This includes changing molecular weight, hydrophobicity, and steric properties of substituents to optimize the balance between synthesis ease and antibacterial activity against KAS enzymes.
2Reliability
If thiolactomycin binds to KAS enzymes with slow onset kinetics, then binding affinity is improved, but inhibition effectiveness is reduced
Solution Approach 1:
The patent applies preliminary action by designing thiolactomycin analogs that pre-position functional groups to interact with apo-KasA and acyl-enzyme intermediates before full inhibition occurs. This allows the compound to establish binding affinity rapidly while maintaining effectiveness against the enzyme target.
Solution Approach 2:
The patent utilizes intermediary mechanisms by targeting both apo-KasA and acyl-enzyme intermediates as binding sites. The thiolactomycin analogs act as mediators that can bind to multiple enzyme forms, thereby resolving the contradiction between binding affinity and inhibition effectiveness through multi-stage inhibition.
Data Source
AI summary
This invention provides a compound having the structurewherein R1 is H,whereinn and q are independently an integer from 0 to 8;A is absent or present and when present iswherein m is an integer from 0 to 8;R3 is an amino, alkyl, aryl, heteroaryl, diol, piperazine, morpholine, piperidine, triazole, azide or biphenyl, each with or without substitution, branched or unbranched, orandR4 is alkyl, aryl, or heteroaryl, each with or without substitution, branched or unbranched,R2 is H, CH3, or alkyl, aryl, heteroaryl, pyrrole, diazole, or triazole, each with or without substitution, branched or unbranched, orwhereinn and q are independently an integer from 0 to 8;A is absent or present and when present isandR6 is azide, methoxy, trifluoromethyl, biphenyl, substituted phenyl, substituted triazole, or alkyl, aryl or heteroaryl, with or without substitution, branched or unbranched,when R1 is H then R2 is other than H or CH3, and when R2 is H or CH3 then R1 is other than H,or a pharmaceutically acceptable salt thereof.